Summary Freund's adjuvant produced severe in¯ammation that augments development of antibodies. Thus, mixed administration of antigens with adjuvant was not required as long as in¯ammation was induced in the hosts. Since macrophage activation for phagocytosis and antigen processing is the ®rst step of antibody development, in¯ammation-primed macrophage activation plays a major role in immune development. Therefore, macrophage activating factor should act as an adjuvant for immunization. The in¯ammation-primed macrophage activation process is the major macrophage activating cascade that requires participation of serum vitamin D 3 -binding protein (DBP; human DBP is known as Gc protein) and glycosidases of B and T lymphocytes. Stepwise incubation of Gc protein with immobilized b-galactosidase and sialidase e ciently generated the most potent macrophage activating factor (designated GcMAF) we have ever encountered. Administration of GcMAF (20 or 100 pg/mouse) resulted in stimulation of the progenitor cells for extensive mitogenesis and activation of macrophages. Administration of GcMAF (100 pg/mouse) along with immunization of mice with sheep red blood cells (SRBC) produced a large number of anti-SRBC antibody secreting splenic cells in 2±4 days. Thus, GcMAF has a potent adjuvant activity for immunization. Although malignant tumours are poorly immunogenic, 4 days after GcMAF-primed immunization of mice with heat-killed Ehrlich ascites tumour cells, the ascites tumour was no longer transplantable in these mice.